Grail Stock Surges 55% Following FDA Panel Support for Cancer Test

Key Facts

1Grail's stock surged 55% this week following a favorable vote from an FDA advisory committee.

2The vote on the efficacy of the Galleri test was close, reflecting ongoing concerns regarding its effectiveness.

Grail's stock surged 55% this week following a favorable vote from an FDA advisory committee. The Motley Fool reported that the panel backed the efficacy of the Galleri test, a multi-cancer early detection tool, marking a significant step toward full regulatory approval.

The vote on the efficacy of the Galleri test was close, reflecting ongoing concerns regarding its clinical effectiveness. This committee support is considered a critical milestone for Grail to secure insurance coverage and drive broader market adoption of the screening technology.